PDCD1 and nasopharyngeal carcinoma: The use of anti-PD-1 therapy in patients with NPC is further supported by the results of two phase I/II studies with anti-PD-1 antibody alone in patients with refractory NPC resulting in overall response rates of 20.5–25.9% [9,10].